Boehringer Ingelheim Press Releases

Quick access for journalists to the latest press releases that cover corporate, research & development, prescription, industrial, animal health and consumer pharmaceutical news.

Information for...

General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US Journalists Jobseekers

PRESS RELEASE

Press Release Overview

Here you can find an overview list of our recent Press Releases.

Read more
PRESS RELEASE 15 Nov 2018 at 12:30

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Read more on
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
PRESS RELEASE 07 Nov 2018 at 09:00

Boehringer Ingelheim becomes an official partner to CatCareforLife

Read more on
Boehringer Ingelheim becomes an official partner to CatCareforLife
- Ribbon-cutting in Fremont
PRESS RELEASE 31 Oct 2018 at 12:00

Boehringer Ingelheim achieves next expansion milestone in biologics production in the US

Read more on
Boehringer Ingelheim achieves next expansion milestone in biologics production in the US
- Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animals
PRESS RELEASE 26 Oct 2018 at 11:00

Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animals

Read more on
Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animals
- bvdzero.com
PRESS RELEASE 23 Oct 2018 at 15:00

Boehringer Ingelheim announces the winners of 2018 BVDzero Case Awards

Read more on
Boehringer Ingelheim announces the winners of 2018 BVDzero Case Awards
PRESS RELEASE 19 Oct 2018 at 12:00

Real-world study shows using Giotrif^®/Gilotrif^® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC

Read more on
Real-world study shows using Giotrif^®/Gilotrif^® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
PRESS RELEASE 12 Oct 2018 at 13:00

Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in France

Read more on
Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in France
- New Health Project 'Elephants' in India
PRESS RELEASE 12 Oct 2018 at 10:00

Ingelheim increases awareness of health with the micro enterprise project ‘Elephants’ in South India

Read more on
Ingelheim increases awareness of health with the micro enterprise project ‘Elephants’ in South India
PRESS RELEASE 11 Oct 2018 at 07:00

2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in animal health

Read more on
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in animal health
PRESS RELEASE 28 Sep 2018 at 08:00

Boehringer Ingelheim is committed to joining forces in the global fight against rabies

Read more on
Boehringer Ingelheim is committed to joining forces in the global fight against rabies
PRESS RELEASE 27 Sep 2018 at 08:00

New vaccine against Bovine Respiratory Disease: Boehringer Ingelheim reaffirms its focus on prevention

Read more on
New vaccine against Bovine Respiratory Disease: Boehringer Ingelheim reaffirms its focus on prevention
PRESS RELEASE 26 Sep 2018 at 10:00

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

Read more on
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
PRESS RELEASE 25 Sep 2018 at 15:45

Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)

Read more on
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)
PRESS RELEASE 13 Sep 2018 at 08:00

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Read more on
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
- Boehringer Ingelheim Center
PRESS RELEASE 10 Sep 2018 at 16:30

Changes to the Leadership of Boehringer Ingelheim’s Corporate Department Medicine

Read more on
Changes to the Leadership of Boehringer Ingelheim’s Corporate Department Medicine
PRESS RELEASE 04 Sep 2018 at 14:00

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Read more on
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
PRESS RELEASE 04 Sep 2018 at 10:00

Boehringer Ingelheim launches the first liquid solution for hypertension in cats

Read more on
Boehringer Ingelheim launches the first liquid solution for hypertension in cats
PRESS RELEASE 03 Sep 2018 at 10:00

Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumab

Read more on
Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumab
PRESS RELEASE 21 Aug 2018 at 16:00

New tablet production facility in Ingelheim: Centerpiece for global launches

Read more on
New tablet production facility in Ingelheim: Centerpiece for global launches